AFT Pharmaceuticals (AFT) reported a below expectations 1H23 result with EBIT ex licensing income (underlying EBIT) of NZ$3.4m versus our NZ$5.0m expectation; the key miss relative to our expectations is higher costs and lower gross margins, but we are encouraged by the strong underlying revenue trends (particularly in ANZ) with revenue ahead of our forecasts (NZ$65.8m versus our NZ$61.7m expected)
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.